Partnership between AstraZeneca and the Broad Institute

AstraZeneca and the Broad Institute in Cambridge, Massachusetts have announced a collaboration to identify new chemical compounds targeting bacterial and viral infections that could speed the development of new antibacterial and antiviral drugs (see the joint press release here. Dr. Michael Foley, director of the Broad Institute's Chemical Biology Platform and Dr. Manos Perros, vice president and head of the AstraZeneca Infection Innovative Medicines Unit describe the partnership in this video.